A Big Drug Roundup for Big Pharma

Before you go, we thought you'd like these...
Before you go close icon

In this video, senior health-care analyst David Williamson discusses some big news from a pair of Big Pharma companies and one big biotech. Find out what these drug successes and failures mean for these three stocks as well as their competitors.

One nice thing about Big Pharma is that you get paid to wait for drug approvals with nice, juicy dividends. If you're interested in some of these dividends on your quest for high-yielding stocks, The Motley Fool has compiled a special free report outlining our nine top dependable dividend-paying stocks. It's called  "Secure Your Future With 9 Rock-Solid Dividend Stocks." You can access your complimentary copy today at no cost! Just click here to discover the winners we've picked.

The article A Big Drug Roundup for Big Pharma originally appeared on Fool.com.

Dave Williamson owns shares of Pfizer. Max Macaluso and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend Elan. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners